department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Apellis Pharmaceuticals, Inc. ($APLS) · pharmadog

PUBLIC COMPANY

$APLSApellis Pharmaceuticals, Inc.

Waltham, MA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

2

marketed

2

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

2Marketed

Geographic Atrophy

Paroxysmal Nocturnal Hemoglobinuria

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Apellis Pharmaceuticals, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$APLS

SEC CIK

0001492422

country

US

source

sec_tickers

top tags

AMD1 Ophthalmology1

mentioned in

0news items

entity-linker matched

Apellis Pharmaceuticals, Inc. earnings

Apellis Pharmaceuticals, Inc.

$APLS41.030.00%

Active trials

phase3An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDcompletedn=792
phase3Pegcetacoplan Long Term Safety and Efficacy Extension Studycompletedn=137
phase2Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGNcompletedn=13
phase3An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritisactive not recruitingn=100
phase2A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratiorecruitingn=240
phase3A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantationrecruitingn=320
—A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degenerationactive not recruitingn=300
phase3Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritiscompletedn=124

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Insider activity

source: SEC Form 4

open-market buys + sells

Feb 11, 26SELLDeLong Mark Jeffrey· Chief Business & Strat Officer368 sh @ $22.15−$8K↗

routine RSU / option mechanics (6)

Apr 17, 26giftSullivan Timothy Eugene · Chief Financial Officer11,096 sh
Apr 17, 26giftSullivan Timothy Eugene · Chief Financial Officer11,096 sh
Apr 6, 26otherO'Brien Stephanie Monaghan · director5,750 sh
Mar 11, 26giftFrancois Cedric · Chief Executive Officer64,869 sh
Mar 11, 26giftFrancois Cedric · Chief Executive Officer64,869 sh
Feb 27, 26grantDolsten Mikael · director24,135 sh

Data sources

last refreshed 19m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$APLS41.030.00%